PCV94 Dronedarone is Cost-Effective for the Prevention of Downstream Cardiovascular Morbidity and Mortality in Australian Patients with Atrial Fibrillation

Abstract

mation were calculated. RESULTS: Taking into account the results from MC simulations, the PTA/S alternative is the most expensive and less effective (€ 24,581 and 6.857 QALYs), but attending to small differences and the large variability on results between alternatives, these results are not conclusive. The least costly alternative is PTA/S/BP (€ 18,351), with an effectiveness of 7.049 QALYs. PTA/S/BP shows higher effectiveness than PTA/S, but lower effectiveness than BP (7.281 QALYs). The cost of the BP alternative is € 24,056. PTA/S/BP and BP alternatives show higher probabilities of being efficient alternatives. If the willingness to pay is € 30,000/QALY, opportunity cost of implementing PTA/S/BP would exceed € 15,000 per patient treated. CONCLUSIONS: Although the results of effectiveness identified PTA/S/BP as the most efficient alternative for a willingness to pay less than € 40,000/QALY, the probability of making a proper decision is only about 50%. This situation, together with the high opportunity costs, encourages the development of new clinical trials or observational studies in our environment in order to remove uncertainty over the results.